ZyVersa Therapeutics, Inc. ZVSA
0.10
0.00
0.00%
as of 24 Sep
- Market cap
- $970.0K
- P/E
- 0.0×
Follow ZVSA
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(112.65%) | 1,093.82% | 1,289.40% | 817.13% | |
| (42.40%) | (251.13%) | (236.93%) | (225.42%) | ||
ROIC |
(80.31%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
68.29% | 218.31% | 201.45% | 173.38% | |
Free Cash Flow per Share |
(1.06) | (0.76) | (0.86) | (0.51) | |
Free Cash Flow |
(5.12) | (5.92) | (5.11) | (4.14) | |
| Other line items | |||||
Cash ROIC |
(83.00%) | 52.83% | 41.63% | 29.96% | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | (0.05) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.62 | 0.23 | 0.21 | 0.17 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.06) | (0.76) | (0.86) | (0.51) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates